Despite promising preclinical efficacy in PI3K-pathway-dependent prostate cancer models [12], [13], [14], there have been only sporadic clinical responses in single-agent trials with rapamycin analogs (rapalogs, eg CCI-779, RAD001) targeting the PI3K-pathway via allosteric inhibition of mTORC1 [15], [16]. The gene discussed is PIK3CA; the disease is prostate cancer.